title: Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study.
abstract: OBJECTIVE
  Several studies in vitro or in rodent models have suggested a potential relationship between angiotensin-converting enzyme (ACE) inhibition and the insulin-like growth factor 1 (IGF-1) axis. However, this relationship has only rarely been investigated in humans. The aim of the present cross-sectional study was to assess the association of ACE inhibitors with free IGF-1 and IGFBP-3 in the blood of older hypertensive adults.
  
  
  METHODS
  Data are from the baseline evaluation of the IlSIRENTE study, which enrolled 364 subjects aged 80 or older. For the present study we selected a subpopulation of 264 hypertensive participants without congestive heart failure. Free IGF-1 and IGFBP-3 in the blood were measured by a radioimmunoassay method. Analyses of covariance were performed to evaluate the differences in free IGF-1 and IGFBP-3 levels according to the use of ACE inhibitors.
  
  
  RESULTS
  The mean age of participants was 85.7 years (SD: 4.9), 170 (64%) were women and 123 (47%) were using an ACE inhibitor. Following adjustment for potential confounders, the concentration of free IGF-1 was slightly, but not significantly higher among ACE inhibitor users than among non-users (0.74 vs. 0.65 ng/mL; p=0.20). In contrast, ACE inhibitor users had a significantly higher IGFBP-3 serum levels than non-users (4821 vs. 4330 ng/mL; p=0.005). In addition, the concentration of IGFBP-3 was significantly higher among ACE inhibitors users than among non-users of antihypertensive drugs (p=0.02) and users of other antihypertensive drugs (p=0.01).
  
  
  CONCLUSIONS
  Among hypertensive older adults, ACE inhibitors use is associated with higher IGFBP-3 levels.
authors.affiliation: Department of Geriatrics, Catholic University of the Sacred Heart, Rome, Italy. graziano_onder@rm.unicatt.it
authors.forename: Graziano
authors.initials: G
authors.lastname: Onder
authors.forename: Rosa
authors.initials: R
authors.lastname: Liperoti
authors.forename: Andrea
authors.initials: A
authors.lastname: Russo
authors.forename: Ettore
authors.initials: E
authors.lastname: Capoluongo
authors.forename: Angelo
authors.initials: A
authors.lastname: Minucci
authors.forename: Paola
authors.initials: P
authors.lastname: Lulli
authors.forename: Matteo
authors.initials: M
authors.lastname: Cesari
authors.forename: Marcello
authors.initials: M
authors.lastname: Maggio
authors.forename: Roberto
authors.initials: R
authors.lastname: Bernabei
authors.forename: Francesco
authors.initials: F
authors.lastname: Landi
mesh_terms: D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I